GemciTest: A New In-Vitro Diagnostic to predict the patient response in pancreatic cancer treatment

Acobiom proposes a new In-Vitro Diagnostic (IVD), based on a new Blood RNA-biomarker signature, able to predict the response to Gemcitabine in Metastatic Pancreatic Cancer and to prognose a 14.9-month survival.

Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer, and about 98% of them will die from the disease (source: World Pancreatic Cancer Coalition). In 2016, pancreatic cancer moved from the 4th leading cause of cancer-related death in the U.S. to the 3rd, surpassing breast cancer (source: Pancan).
After years of silent progression, 80% of patients diagnosed with pancreatic cancer have non-resectable tumors. For those, the only drug therapeutic option is chemotherapy. The Gemcitabine treatment in pancreatic cancer is generally associated with a 6.7-month survival.

Acobiom discovered and patented a combination of blood RNA-biomarkers that is correlated to the prediction of a 14.9-month survival for a sub-population of patients diagnosed with Pancreatic Cancer and treated by Gemcitabine.

From this new Blood RNA-biomarker signature, Acobiom developed a new In-Vitro Diagnostic, called GemciTest, based on qRT-PCR technology.

Hence, the GemciTest can identify the patients suffered from pancreatic cancer that are the most likely to benefit from gemcitabine.

To illustrate the overall survival benefits of the GemciTest, the sub-population of patients identified by the GemciTest is characterized by the following rates:

> 65% of them are alive 12 months after the diagnostic of the disease (versus 35%* for the patients treated by the combination Abraxane+Gemcitabine and 24% for the patients treated blindly by gemcitabine),
> 50% of them are alive 14.9 months after the diagnostic of the disease (versus 20%* for the patients treated by the combination Abraxane+Gemcitabine and 11% for the patients treated blindly by gemcitabine).

(*: data from « Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine », Von Hoff et al, N Engl J Med. 2013)

Acobiom GemciTest OS pub.OK

The Cancer hospital (CGFL) of Dijon (France) is currently evaluating in a 2-year clinical study the prognostic value of the GemciTest on every patients diagnosed with pancreatic cancer and treated by chemotherapy. The Chief Investigator for this study is Professor François Ghiringhelli, Centre de Lutte Contre le Cancer (CGFL, Dijon, France).

The benefits of the GemciTest on clinical and economical aspects are described on the following document: The Gemcitest flyer and in the following presentation: Gemcitest

The SOP of the GemciTest is available for routine analyses and the diagnostic can be ordered for « Research Use Only » (RUO).

If you need more information, please contact our business development department (T: +33(0)467 419 748, Email: busdev@acobiom.com).